On July 30th, Gelun Hui reported the 2024 semi-annual report of Shengnuo Biological (688117.SH), with a revenue of 0.199 billion yuan, a year-on-year increase of 14.44%; a net income of 21.7876 million yuan attributable to shareholders of listed companies, a year-on-year increase of 8.14%; a net income of 19.122 million yuan attributable to shareholders of listed companies after deducting non-recurring gains and losses, a year-on-year increase of 106.55%; and an EPS of 0.19 yuan.
During the reporting period, the operating income increased by 14.44% compared to the same period last year, mainly due to the increase in sales of injection growth hormone and injection Atorvastatin after winning the bid in the June 2023 centralized procurement, which caused a 48.27% increase in sales of preparations compared to the same period last year. Secondly, overseas sales of API increased by 97.51% compared to the same period last year.